Metformina + Sitagliptina Teva (Metformin Hydrochloride, Sitagliptin)

Metformin acts primarily by decreasing hepatic glucose production and increasing peripheral insulin sensitivity. Sitagliptin inhibits the enzyme dipeptidyl peptidase‑4, leading to higher levels of incretin hormones (GLP‑1 and GIP) that stimulate insulin release and suppress glucagon in a glucose‑dependent manner. Together they lower fasting and post‑prandial glucose.

The specific dose and dosing schedule are determined by the prescribing healthcare professional based on individual patient factors such as renal function, glycaemic targets, and concomitant medications. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety data for the combination in pregnancy and lactation are limited. The prescriber must weigh potential benefits against possible risks to the fetus or infant. Generally, metformin may be continued if clearly needed, while sitagliptin is usually avoided unless the benefit justifies potential exposure.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with metformin monotherapy, the addition of sitagliptin offers greater HbA1c reduction and better post‑prandial glucose control. Unlike sulfonylureas, the combination has a lower intrinsic risk of hypoglycaemia. It also provides an oral alternative to injectable GLP‑1 receptor agonists, though efficacy may be modest in patients with very high baseline glucose.

Metformina + Sitagliptina Teva should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the container tightly closed and out of reach of children. No refrigeration is required for this oral tablet formulation.

The medication is taken orally, usually with meals to reduce gastrointestinal discomfort. Tablets should be swallowed whole with a full glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider and should not crush or chew the tablets unless specifically instructed.

The most serious adverse events include lactic acidosis (primarily linked to metformin) and severe hypoglycaemia when used with insulin or sulfonylureas. Pancreatitis has also been reported with sitagliptin. Patients should seek immediate medical attention if they experience unexplained muscle pain, rapid breathing, severe abdominal pain, or signs of low blood sugar.

The combination is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin, sitagliptin, or any excipients, and those with a history of lactic acidosis. Caution is also advised for individuals with significant hepatic disease, heart failure, or chronic alcohol abuse.